Parkinson's disease is a progressive neurodegenerative disorder that is common, age-related and chronic.
It is caused by loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain.
Onset of symptoms and progression of the disease is gradual.
Motor signs and symptoms include resting tremor, rigidity, bradykinesia and postural instability.
Parkinson's disease dementia indicates loss of intellectual functions
including memory, significant deterioration in the ability to carry out
day-to-day activities and changes in social behavior are often noted.
Ballard C, Ziabreva I, Larsen JP, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006 Dec;67(11):1931-1934. PMID: 17159096
Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003 Mar;60(3):387-392. PMID: 12633150
Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011 Feb;68(2):165. doi: 10.1001/archneurol.2010.260. Accessed 16 Jun 2011. PMID: 20937936
Fargel M, Grobe B, Oesterle E, et al. Treatment of Parkinson's disease: a survey of patients and neurologists. Clin Drug Investig. 2007;27(3):207-218. PMID: 17305415
Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint Task Force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol. 2006 Nov;13(11):1186-1202. PMID: 17038032
Lebrun-Frenay C, Borg M. Choosing the right dopamine agonist for patients with Parkinson's disease. Curr Med Res Opin. 2002;18(4):209-214. PMID: 12201621
Lim SY, Fox SH. An update on the management of Parkinson's disease. Geriatr Aging. 2008;11(4):215-222
Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002 Jan;58(1):011-17. PMID: 11781398
Miyasaki JM, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr;66(7):996-1002. PMID: 16606910
Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr;66(7):983-995. PMID: 16606909
Rao SS, et al. Parkinson's disease: diagnosis and treatment. Am Fam Physician. 2006 Dec;74(12):2046-2054. PMID: 17186710
Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001 Jun;56(11)(Suppl 5):S1-S88. PMID: 11402154
Samuel M, Maidment I, Boustani M, Fox C. Clinical management of Parkinson's disease dementia: pitfalls and progress. Adv Psychiatr Treat. 2006;12:121-129
Seppi K, Rascol O. Dementia with Lewy bodies and Parkinson disease with dementia: can MRI make the difference?. Neurology. 2007 Aug;69(8):717-718. PMID: 17709701
Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002 May;359(9317):1589-1598. PMID: 12047983
Truong DD, Wolters EC. Recognition and management of Parkinson's disease during the premotor (prodromal) phase. Expert Rev Neurother. 2009 Jun;9(6):847-857. PMID: 19496688
Suchowersky O, et al. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr;66:976-982. PMID: 16606908
Suchowersky O, et al. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr;66(7):968-975. PMID: 16606907
Young R. Update on Parkinson's disease. Am Fam Physician. 1999 Apr;59(8):2155-2167,2169-2170. PMID: 10221302
Jankovic J, Lang AE. Movement disorders: diagnosis and assessment. In: Bradley W, Daroff R, Fenichel G, et al, eds. Bradley: Neurology in Clinical Practice. 5th ed. Philadelphia: Butterworth Heinemann Elsevier; 2008
Scottish Intercollegiate Guidelines Network. Management of patients with dementia: national clinical guideline. SIGN. http://www.sign.ac.uk. Feb 2006.
National Collaborating Centre for Mental Health, Social Care Institute for Excellence, National Institute for Clinical Excellence. Dementia: a NICE-SCIE guideline on supporting people with dementia and their carers in health and social care. Social Care Institute for Excellence. http://www.scie.org.uk/publications/misc/dementia/dementia-fullguideline.pdf. 2007
Ministry of Health Malaysia, Malaysian Psychiatric Association, Academy of Medicine Malaysia. Malaysian Society of Neurosciences. Clinical practice guidelines: management of dementia. 2nd ed. 2009
Ministry of Health Singapore. Dementia: MOH clinical practice guidelines 3/2007. MOH (Singapore). http://www.moh.gov.sg. 2007
Scottish Intercollegiate Guidelines Network. Diagnosis and pharmacological management of Parkinson's disease. SIGN. http://www.sign.ac.uk/pdf/sign113.pdf. Jan 2010
National Institute of Neurological Disorders and Stroke. Parkinson’s Disease: hope through research. NINDS. http://www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease.htm. 2001
National Institute for Health and Care Excellence. Parkinson’s disease: diagnosis and management in primary and secondary care. CG 35. NICE. http://guidance.nice.org.uk/CG35. 2006
Swanberg MM, Kalapatapu RK. Parkinson disease dementia. eMedicine. Jan 2010
Tarsy D. Pharmacologic treatment of Parkinson disease. UpToDate. http://www.uptodate.com/contents/pharmacologic-treatment-of-parkinson-disease. Feb 2011. Accessed 09 Sep 2011
Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint Task Force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. 2006 Nov;13(11):1170-1185. PMID: 17038031
Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013 Jan;20(1):5-15. doi: 10.1111/j.1468-1331.2012.03866.x. PMID: 23279439
Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011 Oct;26(Suppl 3):S2-S41. doi: 10.1002/mds.23829. PMID: 22021173
Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011 Oct;26(Suppl 3):S42-S80. doi: 10.1002/mds.23884. Accessed 5 Mar 2015. PMID: 22021174
Zhao YJ, Wee HL, Chan YH, et al. Progression of Parkinson’s disease as evaluated by Hoenhn and Yahr stage transition times. Mov Disord. 2010 Apr;25(6):710-716. doi: 10.1002/mds.22875. PMID: 20213822
National Institute for Health and Care Excellence . Postural hypotension in adults: fludrocortisone. NICE. https://www.nice.org.uk/advice/esuom20/chapter/key-points-from-the-evidence. 2013.
Sanchez-Ferro A, Benito-Leon J, Gomez-Esteban JC. The management of orthostatic hypotension in parkinson’s disease. Front Neurol. 2013 Jun;4(64). doi: 10.3389/fneur.2013.00064. PMID: 23772219
Dickson DW, Fujishiro H, Orr C, et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord. 2009 Dec;15(Suppl 3):S1-S5. doi: 10.1016/S1353-8020(09)70769-2. PMID: 20082965
Tarsy D. Management of comorbid problems associated with Parkinson disease. UpToDate. www.uptodate.com. 2016 May.
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.